ClinicalTrials.Veeva

Menu

Dupilumab Compassionate Use Study

S

Sally E. Wenzel MD

Status

Conditions

Asthma

Treatments

Drug: Dupilumab

Study type

Expanded Access

Funder types

Other

Identifiers

NCT03020810
PRO16120334

Details and patient eligibility

About

This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.

Full description

This study is being undertaken to determine whether dupilumab has efficacy in extremely severe asthma, and to allow a very severe asthma patient, who has been tried on nearly every immunosuppressive drug, early access to a potentially effective therapy.

The patient will continue in the study indefinitely. Safety will be evaluated and serious adverse events will be reported.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Sever systemic corticosteroid dependent asthma for more than 5 years

Exclusion criteria

  • Disease other than asthma
  • Circulation eosinophils more than 1500/ul
  • Current smoker or more than 10 pack years

This is a single-patient study. The University of Pittsburgh site is not enrolling new patients.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems